Carl Icahn said now that MedImmune’s (Nasdaq: MEDI) board has announced it intends to sell the company, he no longer intends to put forth an opposition slate. Icahn said he will closely monitoring the Company’s efforts and reserves the right to launch a proxy contest in the event that MedImmune does not successfully complete the sale transaction.
Several weeks ago Icahn informed the company he believed the best course of action was to put the company up for sale and planed to nominate an opposing slate at the upcoming 2007 annual meeting.
Smart Investors Are Quietly Loading Up on These “Dividend Legends”
If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats.
There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside.
If you’re tired of feeling one step behind in this market, this free report is a must-read for you.
By providing your email address, you agree to receive communications from us regarding website updates and other offerings that may be of interest to you.
You have the option to opt-out of these emails at any moment. For more information, please review our Disclaimer and Terms of Use.
